The University has signed a licence agreement with life sciences giant Merck for pioneering fluorescent probe technology that helps understand how disease progresses.

Edinburgh Research & Innovation (ERI), the commercialisation arm of The University of Edinburgh, has entered into a licence agreement with the life science business of Merck, a leading science and technology company in healthcare, life science and performance materials.

The licence agreement provides Merck with access to a pioneering technology to prepare fluorescent peptides as tools to understand how disease progresses in early stages and with improved resolution.

“At Merck, we are always looking for innovative ideas to enhance our customers’ research efforts. This compound from the University of Edinburgh offers researchers a way to fluorescently label peptides that has minimal interference with peptide structure. This will enable biological discovery and complement our portfolio of chemical biology tools,” said Udit B